Drug persistency patterns for patients treated with rivastigmine or donepezil in usual care settings.

@article{Mauskopf2005DrugPP,
  title={Drug persistency patterns for patients treated with rivastigmine or donepezil in usual care settings.},
  author={Josephine A. Mauskopf and Clark Paramore and Won Chan Lee and Edward H. Snyder},
  journal={Journal of managed care pharmacy : JMCP},
  year={2005},
  volume={11 3},
  pages={
          231-51
        }
}
OBJECTIVE To compare levels of persistency with 2 cholinesterase (ChE) inhibitors--rivastigmine and donepezil--for the treatment of Alzheimer's disease (AD) through the use of administrative claims data. METHODS This retrospective cohort study identified treatment-naive, community-based AD patients having an initial prescription (index event) for rivastigmine or donepezil between June and December 2000, in the United States, from pharmacy claims in a proprietary administrative claims database… 

Figures and Tables from this paper

Persistence with Cholinesterase Inhibitor Therapy for Dementia

Among possible factors affecting persistence of ChEI therapy for dementia, choice of drug, ease of administration and previous treatment appear to be important.

Discontinuation of Cholinesterase Inhibitor Treatment and Determinants thereof in the Netherlands

Assessment of ChEI discontinuation in daily practice in the Netherlands and to seek its determinants for early (≤6 months) discontinuation and, separately, for late discontinuation during a subsequent 30-month follow-up among those persisting with treatment for >6 months differed somewhat from associations with discontinuation before 6 months.

Predictive factors of discontinuation and switch of cholinesterase inhibitors in community-dwelling patients with Alzheimer’s disease

This study highlights four types of predictors of switch or discontinuation, reflecting disease progression, reconsideration of ChEI benefits, adverse drug reactions to ChEIs and inappropriate concurrent use of anticholinergic drugs.

A 2-Year Prospective Cohort Study of Antidementia Drug Non-Persistency in Mild-to-Moderate Alzheimer's Disease in Europe

Several predictors were identified: adverse drug events and their predisposing factors, perceived loss of efficacy or disease progression on cognitive or functional scales, behavioural disturbances, hospitalization and professional practices, which implies a need for harmonization in AD drug prescription practice.

Drug persistency of cholinesterase inhibitors for patients with dementia of Alzheimer type in Korea

The 1-year persistency rate of ChEIs for AD patients in Korea did not reach those of previous researches in other countries, and patients less likely to remain on therapy should be especially monitored to optimize treatment persistence.

Discontinuation of donepezil for the treatment of Alzheimer's disease in geriatric practice

Donepezil was frequently discontinued, and the rate of discontinuation was higher in patients with advanced dementia, as surveyed in a Japanese geriatric outpatient clinic in a university hospital.

Comparison of persistence rates of acetylcholine-esterase inhibitors in a state Medicaid program

Among patients persisting with ChEI medication for at least 12 months, users of donepezil were slightly more likely to continue to persist at 24 months, and one-year persistence rates were similar between different ChEIs.

Clinical Compliance of Donepezil in Treating Alzheimer’s Disease in Taiwan

Findings indicate that early intervention with ChEI in patients with AD should be emphasized and may lead to a better clinical adherence, and the clinical adherent rate was higher in theCDR-0.5 group than in the CDR-2.0 group with significant difference.

Rivastigmine transdermal system for the treatment of mild to moderate Alzheimer’s disease

The aim of this review was to provide a concise, comprehensive overview of the clinically relevant safety, tolerability and efficacy information available for the rivastigmine transdermal system, which provides a viable treatment option for patients with mild to moderate AD.

Antidementia drug use among community-dwelling individuals with Alzheimer’s disease in Finland: a nationwide register-based study

Investigating the prevalence of acetylcholinesterase inhibitor (AChEI) and memantine use, duration of treatment, concomitant use of these drugs, and factors associated with the discontinuation during 2006–2009 found the low rate of discontinuation is consistent with the Finnish Care Guideline but in contrast to the results reported from many other countries.
...

References

SHOWING 1-10 OF 30 REFERENCES

Comments on Efficacy and Safety of Rivastigmine in Patients with Alzheimer's Disease who Failed to Benefit from Treatment with Donepezil

It was 5 weeks to 4.5 months before patients were again receiving effective doses of a cholinesterase inhibitor, making it unlikely that they would regain benefits lost during this time, thus raising both clinical and ethical questions.

A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer's disease.

Using the recommended dosing schedules, donepezil was better tolerated with fewer discontinuations due to AEs, and both agents improved cognition to a similar extent.

Efficacy and Safety of Rivastigmine in Patients with Alzheimer's Disease who Failed to Benefit from Treatment with Donepezil

Rivastigmine treatment appears to be beneficial in AD patients who have previously failed to benefit from, or were unable to tolerate treatment with, donepezil, consistent with reports from previous clinical studies.

The effect of donepezil therapy on health costs in a Medicare managed care plan.

By improving cognitive and daily functioning, donepezil may lower costs by improving medical management by reducing the cost of medical services and prescription drugs.

Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer’s disease

The results of the cost-effectiveness model presented here suggest that donepezil may be cost-effective but additional controlled data on long-term drug efficacy are needed.

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease

The data indicate that donepezil is a well-tolerated drug that improves cognition and global function in patients with mild to moderate AD.

How Many Patients Complete an Adequate Trial of Donepezil?

Pharmacy claims data were used to evaluate medication adherence among 59 new users of donepezil and suggest that adherence with donepezIL could be improved in clinical practice.

A 52-Week Study of the Efficacy of Rivastigmine in Patients with Mild to Moderately Severe Alzheimer’s Disease

By 52 weeks, patients originally treating with 6–12 mg/day rivastigmine had significantly better cognitive function than patients originally treated with placebo.

Switching cholinesterase inhibitors in patients with Alzheimer's disease.

  • M. Emre
  • Biology, Medicine
    International journal of clinical practice. Supplement
  • 2002
It is suggested that patients not tolerating or not responding to one particular cholinesterase inhibitor may still draw benefits upon switching to another, and several switching studies indicated that a substantial proportion of patients who fail to benefit from treatment with donepezil could draw benefits after being switched to rivastigmine.